Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

870 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 2
1966 1
1968 2
1969 2
1970 6
1971 2
1972 5
1978 1
1979 2
1980 2
1981 7
1982 7
1983 14
1984 12
1985 29
1986 19
1987 21
1988 26
1989 13
1990 37
1991 16
1992 24
1993 18
1994 29
1995 35
1996 34
1997 30
1998 45
1999 31
2000 28
2001 20
2002 38
2003 22
2004 26
2005 25
2006 31
2007 24
2008 24
2009 20
2010 17
2011 18
2012 20
2013 29
2014 23
2015 20
2016 17
2017 16
2018 15
2019 5
Text availability
Article attribute
Article type
Publication date

Search Results

870 results
Results by year
Filters applied: . Clear all
Page 1
Megestrol acetate for treatment of anorexia-cachexia syndrome.
Ruiz Garcia V, et al. Cochrane Database Syst Rev 2013 - Review. PMID 23543530 Free PMC article.
BACKGROUND: This is an updated version of a previously published review in The Cochrane Library (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in cancer-associated anorexia. In 1993, MA was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. ...
BACKGROUND: This is an updated version of a previously published review in The Cochrane Library (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in c …
Megestrol acetate for cachexia-anorexia syndrome. A systematic review.
Ruiz-García V, et al. J Cachexia Sarcopenia Muscle 2018. PMID 29542279 Free PMC article.
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. ...This is an updated version of a Cochrane systematic review first published in 2005 and later updated in 2013 entitled 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. ...
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. ...This is an updated version of a Cochrane systematic review first published in …
Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.
Fox CB, et al. Pharmacotherapy 2009 - Review. PMID 19323618
Although several drug interventions have been employed for this problem, megestrol acetate and mirtazapine are becoming increasingly used for appetite stimulation. ...Therefore, the use of megestrol acetate or mirtazapine for weight loss should be thoroughly evaluated on an individual basis. ...
Although several drug interventions have been employed for this problem, megestrol acetate and mirtazapine are becoming increasingly used for appetite stimulation. ...Therefore, the use of megestrol acetate or mirtazapine for weight loss should be thoroughly evaluated on …
Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.
Nanjappa S, et al. Cancer Control 2016. PMID 27218795
A thorough workup of the case was performed and secondary adrenal insufficiency induced by the administration of megestrol acetate was determined to be the cause. Adrenal insufficiency is a serious disorder that is a potential adverse event of megestrol acetate, a medication used to help patients with cancer cachexia increase their appetite and gain weight. ...
A thorough workup of the case was performed and secondary adrenal insufficiency induced by the administration of megestrol acetate was determined to be the cause. Adrenal insufficiency is a serious disorder that is a potential adverse event of megestrol acetate, a medicat …
Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Ha ES, et al. Drug Des Devel Ther 2015. PMID 26345723 Free PMC article.
The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. ...These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical antisolvent process is a promising approach to improve the dissolution and absorption properties of megestrol acetate....
The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. ...These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical ant …
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
Jatoi A, et al. J Clin Oncol 2002 - Clinical Trial. PMID 11786587
PURPOSE: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia. ...Toxicity was also comparable, with the exception of an increased incidence of impotence among men who received megestrol acetate. ...
PURPOSE: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia. ...Toxicity was also comparable, with the exception of an increased inci …
Using megestrol acetate to ameliorate protein-energy wasting in chronic kidney disease.
Smith CS and Logomarsino JV. J Ren Care 2016 - Review. PMID 26537025
BACKGROUND: Various populations are affected by chronic kidney disease (CKD), and a low dose appetite stimulant megestrol acetate (MA) is sometimes recommended in patients with CKD to ameliorate protein-energy wasting (PEW). ...
BACKGROUND: Various populations are affected by chronic kidney disease (CKD), and a low dose appetite stimulant megestrol acetate (MA) is sometimes recommended in patients with CKD to ameliorate protein-energy wasting (PEW). ...
Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer.
Wen W, et al. Sci Rep 2017. PMID 28986550 Free PMC article.
Megestrol acetate is a frequently used drug in endometrial cancer patients. However, its response rate is only 20-30%. To enhance the activity of megestrol acetate in endometrial cancer patients, we explored the potential of combining natural supplements with megestrol acetate and found that the addition of the natural phenolic compound, pterostilbene, to megestrol acetate resulted in a synergistic inhibition of cancer cell growth in vitro and an enhanced reduction of tumor growth in a xenograft mouse model. ...Our results demonstrated for the first time that the anti-tumor activity of megestrol acetate can be enhanced by combining with pterostilbene, providing an insight into the potential application of pterostilbene and megestrol acetate combination for the treatment of endometrial cancer....
Megestrol acetate is a frequently used drug in endometrial cancer patients. However, its response rate is only 20-30%. To enhance the activity of megestrol acetate in endometrial cancer patients, we explored the potential of combining natural supplements with megestrol
Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state.
Jang K, et al. Drug Des Devel Ther 2014 - Clinical Trial. PMID 25028536 Free PMC article.
RESULTS: The nanocrystal formulation of megestrol acetate was rapidly absorbed in both the fed and fasting states. In the fed state, systemic exposure was comparable between the nanocrystal formulation of megestrol acetate and Megace OS. ...The nanocrystal formulation of megestrol acetate could be more effective in treating patients with cachexia or anorexia....
RESULTS: The nanocrystal formulation of megestrol acetate was rapidly absorbed in both the fed and fasting states. In the fed state, systemic exposure was comparable between the nanocrystal formulation of megestrol acetate and Megace OS. ...The nanocrystal formulation of …
870 results
Jump to page
Feedback